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Purpose: TNBC is generally more aggressive than other BC subtypes and has limited thera-
peutic options. We aimed to construct comprehensive and reliable nomograms to predict the 
OS and BCSS of TNBC patients to offer clinicians therapeutic guidance for improving the 
prognosis of TNBC patients.
Patients and methods: We used the SEER 19 Cancer Registry to identify 21,419 eligible 
TNBC patients diagnosed from January 1, 2010 to December 31, 2015, and divided the 
database randomly into a training cohort (n=10,709) and a validation cohort (n=10,710). 
The log-rank test and Cox analysis together with a competing risk model were utilized to 
identify independent prognostic factors for OS and BCSS, which were then integrated to 
construct nomograms.
Results: According to the training cohort, except for laterality, the following factors were 
all predictive of OS and BCSS: age at diagnosis, race, tumor size, number of positive lymph 
nodes, grade, and histological subtype. The 1-, 3-, and 5-year probabilities of BC-specific 
mortality were 2.7%, 12.5%, and 17.1%, respectively. The precision of the nomograms 
was assessed by the C-index value and calibration plot diagrams. The C-index value were 
0.779 for OS and 0.793 for BCSS in the internal validation and 0.774 for OS and 0.792 
for BCSS in the external validation. Both internal and external calibration plot diagrams 
showed good consistency between the actual and predicted outcomes, especially for 3- and 
5-year OS and BCSS.
Conclusion: These nomograms hold promise as a novel and accurate tool in predicting OS and 
BCSS of TNBC patients and could be used in clinical practice to assist clinicians in developing 
more effective therapeutic strategies and to evaluate prognostic personally.
Keywords: TNBC, nomogram, SEER, cancer-specific survival, prognosis
Introduction
With an estimated 1.8 million new patients each year, BC is the most prevalent cancer 
in women worldwide.1 TNBC, which is a distinct heterogeneous subtype, accounts for 
15%–20% of all BC cases. TNBC is characterized by ≤1% positive immunohistochemi-
cal expression of the estrogen receptor, progesterone receptor, and no amplification of 
human epidermal growth receptor 2 (HER-2).2 Thus, unlike luminal or HER-2+ BC, 
TNBC does not respond to hormonal therapy (such as tamoxifen or aromatase inhibi-
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tors) or targeted therapy (such as trastuzumab or lapatinib). 
Cytotoxic chemotherapy remains the cornerstone for the 
treatment of TNBC.3
TNBC is characterized by its aggressive behavior and a 
poor prognosis; distant visceral metastases can also occur and 
are most frequently found in the lungs and central nervous 
system and less frequently in bone.4 The overall distant recur-
rence risk of TNBC reaches a peak within the first 3 years post 
surgery and becomes less common after 5 years.5–7 Although 
the lifetime with metastasis and recurrence in TNBC is much 
lower than that in other subtypes, TNBC has few treatment 
options and shows a lack of durable treatment responses.8,9 
Due to its particularly malignant behavior, it is important 
to categorize TNBC patients according to their individual 
characteristics to better assess prognosis.
Nomogram is a concrete graphical representation that 
integrates several independent prognostic factors to predict 
a specific end point. In this study, we aimed to construct and 
validate reliable nomograms based on a substantial TNBC 
patient record from the SEER 19 Cancer Registry and to 
compare our nomograms with the traditional TNM stag-
ing system in an effort to help clinicians precisely identify 
high-risk TNBC patients whose survival outcomes might be 
improved by therapy.
Patients and methods
study cohorts
SEER is one of the most representative large-scale tumor 
registration databases in North America, and it contains a 
large amount of evidence-based medical data. The clinico-
pathological information of 21,419 TNBC patients in our 
study was collected from the SEER program from January 
1, 2010 to December 31, 2015. The inclusion criteria were as 
follows: 1) female; 2) BC as the first and only cancer diagno-
sis; 3) diagnosis confirmed by positive histology other than 
by autopsy or a death certificate; 4) older than 20 years; 5) 
unilateral BC; 6) histological grade I–III; and 7) histological 
subtype of infiltrating ductal carcinoma (IDC), infiltrating 
lobular carcinoma (ILC), or others. Patients with unknown 
or ambiguous information were excluded.
We analyzed the patients’ characteristics according to 
the following seven factors: age (20–39, 40–59, 60–79, or 
≥80 years), race (white, black, or others), tumor size (≤2 cm, 
2–5 cm, or >5 cm), number of positive regional nodes (0, 
1–3, 4–9, or ≥10), laterality (left or right), grade (I–III), and 
histology (IDC, ILC, or others). Due to the large number of 
patients and their unknown identity as SEER database does 
not hold identifying patient information, written inform con-
sent was waived, and the study was approved by the ethics 
committee of Shanghai Cancer Center of Fudan University.
statistical analyses
Construction of the nomogram
The eligible patients (n=21,419) were randomly divided 
into the following two equal-sized groups using the func-
tion “sample.int” in R: a training cohort (n=10,709) and a 
validation cohort (n=10,709). The primary outcomes of this 
study were OS and BCSS.
OS was defined as the total survival time from diagnosis 
to BC-related or other causes of death, the last date of follow-
up, or December 31, 2015, if the last follow-up exceeded this 
date. In the training cohort, univariate prognostic factors were 
determined using Kaplan–Meier plots and compared using 
log-rank tests. Significant factors with two-sided P-value 
of <0.05 were entered into the multivariable analysis. With 
clinical relevance taken into account, the associated factors 
identified by the multivariate analysis through Cox propor-
tional hazards models were used to construct a nomogram 
for OS using the R package “rms”.
BCSS was defined as the time from the date of diagnosis 
to the date of death attributed to BC, and deaths from other 
causes were regarded as competing risks. We used the CIF to 
assess the probability of death. A sub-distribution analysis of 
competing risks was performed to construct a competing risk 
model;10 Gray’s11 test was conducted to analyze differences in 
CIF among groups. Thus, a nomogram was developed by the 
integration of prognostic factors with a significant P-value to 
predict 1-, 3-, and 5-year BCSS via the R package “cmprsk”.
Validation of the nomogram
To ensure the predictive accuracy of the nomogram, we vali-
dated the models both internally (1,000 bootstrap resamples in 
the training cohort) and externally (in the validation cohort). 
The degree of fit was assessed by calibration diagrams and the 
C-index value. A calibration diagram was plotted with observed 
survival against the nomogram-predicted probability of survival 
from the model. The C-index value was calculated to assess the 
discriminatory and predictive ability of the model. The C-index 
value varies from 0.5, which represents random chance, to 1.0, 
which indicates a perfect fit. Typically, a C-index value of >0.7 
suggests a reasonable estimation. Validation and calibration of 
the models were also conducted with the R package “rms”.
Comparison of nomograms
We compared the discrimination and prediction ability 
between the traditional TNM prognostic models and our new 
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predictive models based on the C-index value with the R pack-
age “rcorrp.cens” in both the training and validation cohort.
We conducted all statistical analyses with R software, 
version 3.4.2, and SPSS software, version 23 (IBM Corpora-
tion, Armonk, NY, USA).
Results
Demographics and clinicopathological 
characteristics
Through rigorous screening, we identified 21,419 eligible 
TNBC patients in the SEER database who were diagnosed 
from 2010 to 2015. The patients were randomly divided into 
a training cohort and a validation cohort, with 10,709 patients 
in the training cohort and 10,710 in the validation cohort. 
The median age at diagnosis was 57 years (IQR, 47–66 
years), and the median survival time was 29 months (IQR, 
14–48 months) in both cohorts. By the date of last follow-
up, 2,728 (12.74%) patients in the whole cohort died, with 
2,219 (10.36%) deaths attributed to BC and the remaining 
509 (2.38%) attributed to other causes. Detailed baseline 
characteristics are listed in Table 1.
Factors associated with Os
For the training cohort, data on age at diagnosis, race, tumor 
size, number of positive lymph nodes, laterality, grade, and 
histology were collected. The log-rank univariate test showed 
that, except for laterality, the remaining variables should 
be included in the multivariate analysis (Cox proportional 
hazards model), and each of these factors was subsequently 
confirmed to be independent prognostic factors associated 
with OS (Table 2).
Factors associated with BCss
Estimates of the probabilities of death resulting from BC and 
other causes according to clinical characteristics are listed 
in Table 3. The 1-, 3-, and 5-year probabilities of death from 
Table 1 Patients’ demographics and clinicopathological characteristics
Variables All patients Training cohort Validation cohort
N=21,419 N=10,709 N=10,710
n % n % n %
age (years)
20–39 2,063 9.63 1,034 9.66 1,029 9.61
40–59 10,198 47.61 5,111 47.73 5,087 47.5
60–79 7,951 37.12 3,990 37.26 3,961 36.98
≥80 1,207 5.64 574 5.36 633 5.91
Race
White 15,330 71.57 7,643 71.37 7,687 71.77
Black 4,448 20.77 2,241 20.93 2,207 20.61
Othersa 1,641 7.66 825 7.7 816 7.62
size
≤2 9,812 45.81 4,898 45.74 4,914 45.88
2–5 9,512 44.41 4,755 44.4 4,757 44.42
>5 2,095 9.78 1,056 9.86 1,039 9.7
Positive lymph nodes
0 14,919 69.65 7,501 70.04 7,418 69.26
1–3 4,386 20.48 2,156 20.13 2,230 20.82
4–9 1,400 6.54 701 6.55 699 6.53
≥10 714 3.33 351 3.28 363 3.39
laterality
left 11,036 51.52 5,574 52.05 5,462 51
Right 10,383 48.48 5,135 47.95 5,248 49
grade
i–ii 3,788 17.69 1,884 17.59 1,904 17.78
iii 17,631 82.31 8,825 82.41 8,806 82.22
histology
iDC 19,836 92.61 9,905 92.49 9,931 92.73
ilC 198 0.92 95 0.89 103 0.96
Othersb 1,385 6.47 709 6.62 676 6.31
Notes: aAmerican Indian/Alaskan native and Asian/Pacific Islander. bOther histologies of invasive BC except iDC and ilC.
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BC were 2.7%, 12.5%, and 17.1%, respectively, while the 
cumulative incidences of death from other causes were 0.9%, 
2.4%, and 3.8%, respectively. Age, tumor size, and number of 
positive lymph nodes had strong correlations with the prob-
ability of death (P<0.001 for all outcomes), while laterality 
was not associated with death. Patients of the black race, those 
with histological grade III tumors, IDC, or ILC, had a higher 
cumulative incidence of death attributed to BC (P<0.001).
nomogram construction and validation
Only the variables that were significantly associated with 
OS and BCSS (P<0.05) were included in the construction of 
nomograms to predict 1-, 3-, and 5-year survival (Figure 1). 
Figure 1 shows that the number of positive lymph nodes 
was the strongest contributor to survival outcome, followed 
by age at diagnosis and tumor size. The C-index values of 
the nomograms in the training cohort were 0.779 (95% CI, 
0.766–0.792) for OS and 0.793 (95% CI, 0.780–0.807) for 
BCSS. For the validation cohort, the C-index values were 
0.774 (95% CI, 0.761–0.787) for OS and 0.792 (95% CI, 
0.778–0.806) for BCSS. Both internal and external calibra-
tion plot diagrams showed good consistency between the 
actual and predicted outcomes, especially for 3- and 5-year 
OS and BCSS (Figures 2 and 3).
Comparison of nomograms
The C-index values of the TNM system nomograms for OS 
and BCSS were, respectively, 0.753 (95% CI, 0.740–0.767) 
and 0.781 (95% CI, 0.767–0.795) in the training cohort, 
which represented a statistically signif icant decrease 
(P<0.001) compared with the nomograms that included 
all independent prognostic factors. Significant differences 
Table 2 Univariate and multivariate analyses of Os in the training cohort
Variables Univariate 
analysis
Multivariate analysis
P-value HR 95% CI P-value
age (years) <0.001***
20–39 Reference
40–59 0.78 0.65–0.93 0.007**
60–79 1.11 0.92–1.34 0.287 
≥80 3.07 2.47–3.81 <0.001***
Race <0.001***    
White  Reference   
Black  1.32 1.16–1.49 <0.001***
Othersa  0.88 0.70–1.10 0.263 
size <0.001***
≤2 Reference
2–5 1.8 1.57–2.07 <0.001***
>5 3.81 3.23–4.48 <0.001***
Positive lymph nodes <0.001***    
0  Reference   
1–3  2.36 2.07–2.70 <0.001***
4–9  4.55 3.85–5.31 <0.001***
≥10  8.02 6.73–9.56 <0.001***
laterality 0.114 
left Reference
Right 0.93 
grade <0.001***    
i–ii  Reference   
iii  1.12 0.96–1.31 0.152 
histology 0.003**
iDC Reference
ilC 0.84 0.54–1.29 0.417 
Othersb 0.71 0.57–0.90 0.004**
Notes: aAmerican Indian/Alaskan native and Asian/Pacific Islander. bOther histologies of invasive BC except iDC and ilC. Two-sided P-values <0.05; **two-sided P-values 
<0.01; ***two-sided P-values <0.001.
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in C-index value were also found in the validation cohort, 
with TNM system nomograms showing C-index values of 
0.751 (95% CI, 0.737–0.765) for OS and 0.787 (95% CI, 
0.773–0.801) for BCSS (P<0.001; Table S1).
To demonstrate the applied value of the nomograms that 
included all meaningful variables, two normal TNBC patients 
were used as examples. One patient was a 45-year-old, white, 
IDC patient with a 1 cm grade I tumor and five positive lymph 
nodes, while the other was a 65-year-old, black, IDC patient 
with a 6 cm grade III tumor and two positive lymph nodes. 
According to the nomograms consisting of tumor size (T) 
and number of positive lymph nodes (N) only (Figure S1), 
the first patient received 105 points with corresponding 1-, 
3-, and 5-year OS probabilities of 0.85–0.90, 0.50–0.60, 
and 0.40–0.50 and 1-, 3-, and 5-year BCSS predictions 
of 0.90–0.95, 0.60, 0.40–0.50, respectively. The second 
patient received 70 points with significantly different 1-, 
3-, and 5-year OS predictions of 0.90–0.95, 0.75–0.80, and 
0.60–0.70 and 1-, 3-, and 5-year BCSS predictions of >0.95, 
0.80–0.85, and 0.70–0.75, respectively. However, according 
to the nomograms including six prognostic factors, the first 
patient scored 127.5 points for both OS and BCSS, indicat-
ing that the 1-year OS and BCSS probabilities were greater 
than 0.90–0.95, those for 3-year OS and BCSS ranged from 
0.70 to 0.75, and those for 5-year OS and BCSS were ~0.60. 
For the second patient, the respective OS and BCSS scores 
were 125 and 115 points, and the corresponding predictions 
for 1-, 3-, and 5-year OS and BCSS were very similar to 
the first patient. Although both patients had the same stage 
IIIA disease, the prognostic outcomes obtained by the TN 
Table 3 The 1-, 3-, and 5-year cumulative incidence of death among patients in the training cohort
Variables Cumulative incidence of death resulting from BC Cumulative incidence of death resulting from 
other causes
1 year 3 years 5 years P-value 1 year 3 years 5 years P-value
All patients 0.027 0.125 0.171  0.009 0.024 0.038  
age (years) <0.001*** <0.001***
20–39 0.018 0.175 0.227 0.001 0.005 0.012
40–59 0.020 0.117 0.158 0.003 0.010 0.015
60–79 0.028 0.107 0.157 0.011 0.031 0.048
≥80 0.106 0.227 0.295 0.058 0.134 0.223
Race    <0.001***    0.199
White 0.025 0.117 0.162  0.009 0.025 0.042  
Black 0.037 0.160 0.219  0.008 0.023 0.028  
Othersa 0.022 0.098 0.129  0.008 0.017 0.021  
size <0.001*** <0.001***
≤2 0.008 0.052 0.087 0.004 0.016 0.029
2–5 0.030 0.146 0.202 0.012 0.028 0.042
>5 0.105 0.374 0.433 0.018 0.043 0.058
Positive lymph nodes    <0.001***    <0.001***
0 0.009 0.056 0.091  0.006 0.019 0.033  
1–3 0.033 0.192 0.255  0.011 0.029 0.048  
4–9 0.104 0.376 0.463  0.019 0.042 0.044  
≥10 0.231 0.589 0.692  0.025 0.058 0.058  
laterality 0.090 0.938
left 0.026 0.131 0.182 0.010 0.024 0.038
Right 0.029 0.118 0.160 0.008 0.024 0.038
grade    <0.001***    0.472
i–ii 0.015 0.094 0.146  0.009 0.028 0.040  
iii 0.030 0.131 0.177  0.009 0.023 0.037  
histology <0.001*** 0.318
iDC 0.027 0.126 0.173 0.008 0.023 0.037
ilC 0.081 0.260 0.283 0.011 0.011 0.011
Othersb 0.021 0.091 0.129 0.012 0.029 0.053
Notes: aAmerican Indian/Alaskan native and Asian/Pacific Islander. bOther histologies of invasive BC except iDC and ilC. Two-sided P-values <0.05; two-sided P-values 
<0.01; ***two-sided P-values <0.001.
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Figure 1 nomograms for predicting the 1-, 3-, and 5-year (A) Os and (B) BCss of TnBC patients with independent prognostic factors.
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Figure 2 internal calibration curves for the 1-, 3-, and 5-year Os (A–C) and BCss (D–F).
Notes: The 45° line represents an ideal match between the actual survival (Y-axis) and the nomogram-predicted survival (X-axis). The perpendicular line indicates the 95% 
Cis.
 
Ca
nc
er
 M
an
ag
em
en
t a
nd
 R
es
ea
rc
h 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
8.
24
6.
2.
19
0 
on
 2
4-
O
ct
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Cancer Management and Research 2018:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
5888
guo et al
0.85 0.90 0.95 1.00
0.85
0.90
0.95
1.00
Predicted 1-year BCSS
A
ct
ua
l 1
-y
ea
r B
C
S
S
0.40 0.50 0.60 0.70 0.80 0.90 1.00
0.40
0.50
0.60
0.70
0.80
0.90
1.00
Predicted 5-year BCSS
A
ct
ua
l 5
-y
ea
r B
C
S
S
0.85 0.90 0.95 1.00
0.85
0.90
0.95
1.00
Predicted 1-year OS
A
ct
ua
l 1
-y
ea
r O
S
0.40 0.50 0.60 0.70 0.80 0.90 1.00
0.40
0.50
0.60
0.70
0.80
0.90
1.00
Predicted 3-year OS
A
ct
ua
l 3
-y
ea
r O
S
0.30 0.40 0.50 0.60 0.70 0.80 0.90 1.00
0.30
0.40
0.50
0.60
0.70
0.80
0.90
1.00
Predicted 5-year OS
A
ct
ua
l 5
-y
ea
r O
S
0.50 0.60 0.70 0.80 0.90 1.00
0.50
0.60
0.70
0.80
0.90
1.00
Predicted 3-year BCSS
A
ct
ua
l 3
-y
ea
r B
C
S
S
A B
DC
E F
Figure 3 external calibration curves for the 1-, 3-, and 5-year Os (A–C) and BCss (D–F).
Notes: The 45° line represents an ideal match between the actual survival (Y-axis) and the nomogram-predicted survival (X-axis). The perpendicular line indicates the 95% 
Cis.
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nomograms were quite different. However, the nomograms 
containing six independent prognostic factors resulted in very 
similar predicted outcomes, which can be partially attributed 
to the patients’ individual clinicopathological characteristics.
Discussion
In the present study, 21,419 eligible patients with TNBC from 
the SEER database were enrolled and analyzed. Except for 
laterality, various independent prognostic factors, including 
age at diagnosis, race, tumor size, number of positive lymph 
nodes, grade, and histological subtype were closely correlated 
with the OS and BCSS outcomes of TNBC. We included these 
risk factors in the construction of nomograms, and both the 
C-index values and the calibration diagrams showed satisfac-
tory robustness when applied to both internal and external 
validation cohorts. Due to the early metastasis and recurrence 
features of TNBC, it is imperative to establish a reliable 
prediction model to guide clinicians in accurately evaluating 
the patients’ condition and rapidly providing effective treat-
ments in an individualized manner. However, no prognostic 
nomogram has been constructed to date for TNBC patients, 
and this was therefore a top priority in our study.
The log-rank test and Cox proportional hazards regres-
sion were used to identify the independent prognostic factors 
for OS, but these tools cannot be applied to BCSS because 
non-BC-specific death might preclude the possibility of 
death resulting from BC, and censoring these data could 
lead to biased results. Therefore, a competing risk model was 
introduced. In this study, the 1-, 3-, and 5-year probabilities 
of death were 3.6%, 14.9%, and 20.9%, respectively, and 
the 1-, 3-, and 5-year cumulative incidences of death from 
BC were 2.7%, 12.5%, and 17.1%, respectively, indicat-
ing a nearly four-fold higher risk of death attributed to BC 
than from other causes. In addition, the 3-year cumulative 
incidence of death resulting from BC was 3.6 times that of 
the 1-year incidence, while the 5-year probability of death 
from BC showed a 36.8% increase compared with the 3-year 
incidence. These results show strong concordance with the 
classical conclusions that TNBC is associated with an early 
peak of recurrence in the first 2 or 3 years after diagnosis, 
which becomes uncommon after 5 years.
Currently, the data are limited and conflicting regarding 
the prognostic impact of age in patients with TNBC. Two 
large Korean registry-based studies found that an age of 
<35 years was a poor prognosticator in patients with lumi-
nal or HER-2 overexpression BC subtypes but not in those 
with TNBC (HR, 1.21; 95% CI, 0.88–1.67; P=0.240).12 
In contrast, in 1,732 patients with primary TNBC treated 
between 1982 and 2008, Liedtke et al13 reported that the 
median disease-free survival for patients aged 31–40 years 
was 4 years (95% CI, 2–5), whereas it was 8 years (95% CI, 
5–14; P=0.0003) and 7 years (95% CI, 6, not reached) for 
patients aged 41–50 or 51–60 years at the time of diagnosis, 
respectively; these data are highly consistent with our study. 
In our nomograms, the HRs of OS and BCSS in different age 
groups formed a U-shaped curve, with younger and older 
patients experiencing worse survival while patients aged 
40–59 years had the best survival. The unique gene expression 
profile of TNBC could explain this phenomenon, as specific 
proliferation-related and stroma-related gene signatures seem 
to be clinically relevant in patients aged ≤40 years as well 
as in the older age groups.14 In addition, as we know from 
previous studies, TNBC occurs more commonly in people 
of black ethnicities.8,9,15 In our study, black ethnicity also 
contributed to a particularly aggressive cancer behavior, 
which could be associated with parity, lack of breast-feeding 
initiation, and obesity as well as genomic differences that 
make TNBC in black patients more aggressive than TNBC 
in white patients,16–18 with several reports reaching the same 
conclusion.19–22
It has been reported that the association between nodal 
spread and tumor size is not present in TNBC, suggesting that 
the TNM staging system may not be sufficient for predicting 
therapeutic outcome in TNBC patients.23,24 In a retrospective 
cohort of 391 TNBC patients with 73.3 months of follow-
up, the relapse-free survival curves generated by the TNM 
staging system were intermingled and showed overlap from 
stages I to IIIA, only substantially separating between stages 
I–IIIA and IIIB–IIIC.25 The eighth edition of the American 
Joint Committee on Cancer staging manual includes both the 
anatomic staging system and a newly proposed prognostic 
staging system that incorporates ER, PR, HER-2 status, and 
histological grade.26 Although TNBC patients are one stage 
higher than patients with luminal or HER-2 overexpres-
sion BC according to the eighth edition,27 the emergence of 
nonanatomic components of TNBC has allowed clinicians 
to understand why survival can vary greatly among TNBC 
patients of the same stage.28 Therefore, the development 
of a robust model including both the prognostic staging 
system and nonanatomic components is urgently needed to 
provide more accurate indications for prognosis and adjuvant 
treatments.
There are some limitations to our study. First, although 
information on radiation therapy and chemotherapy can be 
accessed from the SEER database, these data are not recom-
mended to be included in the survival analysis due to the 
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incompleteness of the variables and biases associated with 
who receives treatment according to the SEER program. 
The database also does not provide details of local recur-
rence, which prevented us from generating an individualized 
estimate of the risk of recurrence. Inherent biases are also 
unavoidable in any retrospective study, and thus, a large-scale, 
multicenter prospective investigation should be conducted 
to confirm our results. Third, the follow-up period was rela-
tively short, as the data on HER-2 status were not available 
in the SEER database until 2010. Thus, we were only able to 
focus on the short-term prognosis of TNBC patients. Finally, 
although we randomly divided eligible patients into training 
and validation cohorts to evaluate the nomograms internally 
and externally, some deficiencies remained. It would be better 
to verify the nomograms prospectively or at least in another 
independent population-based database.
Conclusion
We found six independent prognostic factors (age at diagno-
sis, race, tumor size, number of positive lymph nodes, grade, 
and histological subtype) for OS and BCSS of TNBC patients 
and used these indicators to develop and validate two prog-
nostic nomograms based on a large population cohort. Our 
developed nomograms performed excellently in both training 
and validation cohorts for predicting the 1-, 3-, and 5-year 
OS and BCSS, which may help clinicians evaluate patient 
prognosis and tailor individualized therapeutic regimens.
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Supplementary materials
Table S1 Comparison of C-index values between nomograms of independent prognostic factors and nomograms of tumor size and 
the number of positive lymph nodes
Cohort Nomograms of independent 
prognostic factors
Nomograms of tumor size and 
positive lymph nodes
 
C-index 
value
95% CI C-index 
value
95% CI P-value
Training cohort: Os 0.779 0.766–0.792 0.753 0.740–0.767 <0.001***
Training cohort: BCss 0.793 0.780–0.807 0.781 0.767–0.795 <0.001***
Validation cohort: Os 0.774 0.761–0.787 0.751 0.737–0.765 <0.001***
Validation cohort: BCss 0.792 0.778–0.806 0.787 0.773–0.801 <0.001***
Note: ***Two-sided P-values <0.001.
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Figure S1 nomograms for predicting the 1-, 3-, and 5-year (A) Os and (B) BCss of TnBC patients with tumor size and the number of positive lymph nodes.
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